☆ 4.7 Article

Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer

CANCER (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update

Sharon H. Giordano et al.

Summary: ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations in response to new and practice-changing data, aiming to disseminate updated recommendations in a timely manner to inform health practitioners and the public on the best available cancer care options.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

Fabrice Andre et al.

Summary: This article provides updated recommendations on the appropriate use of breast cancer biomarker assay results in guiding adjuvant endocrine and chemotherapy decisions for early-stage breast cancer. Based on the latest literature and expert consensus, specific biomarker assay results can be used to guide treatment decisions for patients who meet certain criteria. However, other factors such as disease stage, comorbidities, and patient preferences should also be considered.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Editorial Material Oncology

Ki67 as a Companion Diagnostic: Good or Bad News?

Mitch Dowsett et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

N. Harbeck et al.

Summary: Adjuvant abemaciclib combined with endocrine therapy significantly improved invasive disease-free survival in patients with early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic but did not affect the benefits of abemaciclib. The robust treatment benefit of abemaciclib extended beyond the planned 2-year treatment period.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

Torsten O. Nielsen et al.

Summary: Ki67 immunohistochemistry (IHC) is commonly used in breast cancer as a proliferation marker, but its analytical validity has been questioned. The International Ki67 in Breast Cancer Working Group (IKWG) recommends careful preanalytical handling, adoption of a standardized visual scoring method, and participation in quality assurance and quality control programs. Clinical utility of Ki67 IHC in breast cancer care is currently limited to prognosis assessment in stage I or II breast cancer.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Add to Collection

Article Cell Biology

Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration

Samuel C. Y. Leung et al.

HISTOPATHOLOGY (2019)

Add to Collection

Article Oncology

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F. Cardoso et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

J. A. Sparano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Oleg Gluz et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

U. Nitz et al.

ANNALS OF ONCOLOGY (2014)

Add to Collection

Article Multidisciplinary Sciences

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Christina Curtis et al.

NATURE (2012)

Add to Collection

Article Oncology

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

Jack Cuzick et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Oncology

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

Judith Hugh et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Oncology

Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor-Positive Breast Cancer

Frederique Penault-Llorca et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Oncology

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

Maggie C. U. Cheang et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)

Add to Collection

Review Oncology

Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients

R. Stuart-Harris et al.

BREAST (2008)

Add to Collection

Article Oncology

Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial

John M. S. Bartlett et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Review Oncology

Development of the 21-gene assay and its application in clinical practice and clinical trials

Joseph A. Sparano et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Oncology

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer

Giuseppe Viale et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)

Add to Collection

Article Oncology

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

E. de Azambuja et al.

BRITISH JOURNAL OF CANCER (2007)

Add to Collection

Article Oncology

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

Soonmyung Paik et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Add to Collection

Article Medicine, General & Internal

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

S Paik et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.